In an interim analysis 1 of 74 patients with acute, subacute, and chronic 4 native infrainguinal vessel limb ischemia, average Pounce Thrombectomy Platform use time was 20.3 minutes, with 79.7% of patients receiving no additional clot removal treatment of the target lesion after Pounce Thrombectomy Platform use. Device-related adverse events were limited to one report of flow-limiting dissection. 3 "The addition of the Pounce XL Thrombectomy System fulfills our vision of providing a simple, effective platform for removing peripheral arterial blood clots throughout the leg," said Gary Maharaj, President and Chief Executive Officer of Surmodics. "When minutes matter, physicians appreciate the availability of a readily deployable solution with a track record of dependable and safe results. We're proud of the growing clinical adoption of this product and the benefits it is bringing to limb ischemia patients in need of urgent care."